349 related articles for article (PubMed ID: 24759020)
21. [Prognostic factors analysis for R-CHOP regimen therapy in diffuse large B cell lymphoma].
Shen Y; Yao Y; Li JM; Chen QS; You JH; Zhao HJ; Chen S; Shen ZX
Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):252-7. PubMed ID: 18843980
[TBL] [Abstract][Full Text] [Related]
22. The highest prognostic impact of LDH among International Prognostic Indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of rituximab.
Park JH; Yoon DH; Kim DY; Kim S; Seo S; Jeong Y; Lee SW; Park CS; Huh J; Suh C
Ann Hematol; 2014 Oct; 93(10):1755-64. PubMed ID: 25027115
[TBL] [Abstract][Full Text] [Related]
23. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy.
Shi Z; Das S; Okwan-Duodu D; Esiashvili N; Flowers C; Chen Z; Wang X; Jiang K; Nastoupil LJ; Khan MK
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):569-77. PubMed ID: 23540349
[TBL] [Abstract][Full Text] [Related]
24. Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma.
Cox MC; Nofroni I; Ruco L; Amodeo R; Ferrari A; La Verde G; Cardelli P; Montefusco E; Conte E; Monarca B; Aloe-Spiriti MA
Leuk Lymphoma; 2008 Sep; 49(9):1745-51. PubMed ID: 18798109
[TBL] [Abstract][Full Text] [Related]
25. [Prognosis of primary non-Hodgkin's lymphoma of the breast].
Guo HY; Zhao XM; Cao JN; Hu XC; Yin JL; Hong XN; Li J
Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):200-2. PubMed ID: 18756936
[TBL] [Abstract][Full Text] [Related]
26. High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy.
Li ZM; Huang JJ; Xia Y; Zhu YJ; Zhao W; Wei WX; Jiang WQ; Lin TY; Huang HQ; Guan ZZ
Eur J Haematol; 2012 Jun; 88(6):510-7. PubMed ID: 22413767
[TBL] [Abstract][Full Text] [Related]
27. A success story: how a single targeted-therapy molecule impacted on treatment and outcome of diffuse large B-cell lymphoma.
Mian M; Augustin F; Kocher F; Gunsilius E; Willenbacher W; Zabernigg A; Zangerl G; Oexle H; Schreieck S; Schnallinger M; Fiegl M
Anticancer Res; 2014 May; 34(5):2559-64. PubMed ID: 24778077
[TBL] [Abstract][Full Text] [Related]
28. Reassessment of the prognostic factors of international prognostic index (IPI) in the patients with diffuse large B-cell lymphoma in an era of R-CHOP in Chinese population.
Yang S; Yu Y; Jun-Min L; Jian-Qing M; Qiu-Sheng C; Yu C; Wei-Li Z; Jian-Hua Y; Hui-Jin Z; Yan W; Li W; Shu C; Zhi-Xiang S
Ann Hematol; 2009 Sep; 88(9):863-9. PubMed ID: 19205655
[TBL] [Abstract][Full Text] [Related]
29. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
Pfreundschuh M; Kuhnt E; Trümper L; Osterborg A; Trneny M; Shepherd L; Gill DS; Walewski J; Pettengell R; Jaeger U; Zinzani PL; Shpilberg O; Kvaloy S; de Nully Brown P; Stahel R; Milpied N; López-Guillermo A; Poeschel V; Grass S; Loeffler M; Murawski N;
Lancet Oncol; 2011 Oct; 12(11):1013-22. PubMed ID: 21940214
[TBL] [Abstract][Full Text] [Related]
30. [Evaluation of the impact of R-CHOP chemotherapy on efficacy, safety and prognosis in newly diagnosed diffuse large B-cell lymphoma patients and its prognostic impact: a multicenter retrospective study with long term follow-up].
Cheng ZX; Zou SH; Li F; Li JM; Wang JM; Chen FY; Cao JN; Wang C; Wei Z; Cheng YF
Zhonghua Xue Ye Xue Za Zhi; 2012 Apr; 33(4):257-60. PubMed ID: 22781712
[TBL] [Abstract][Full Text] [Related]
31. [Clinical characteristics and prognosis of diffuse large B-cell lymphoma].
Yang BY; Yong WB; Zhu J; Zheng W; Zhang YT; Wang XP; Meng SN
Zhonghua Zhong Liu Za Zhi; 2005 Mar; 27(3):174-6. PubMed ID: 15946571
[TBL] [Abstract][Full Text] [Related]
32. Diffuse large B-cell lymphoma: clinical characterization and prognosis of Waldeyer ring versus lymph node presentation.
Qi SN; Li YX; Wang H; Wang WH; Jin J; Song YW; Wang SL; Liu YP; Zhou LQ; Yu ZH
Cancer; 2009 Nov; 115(21):4980-9. PubMed ID: 19634158
[TBL] [Abstract][Full Text] [Related]
33. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
Natkunam Y; Farinha P; Hsi ED; Hans CP; Tibshirani R; Sehn LH; Connors JM; Gratzinger D; Rosado M; Zhao S; Pohlman B; Wongchaowart N; Bast M; Avigdor A; Schiby G; Nagler A; Byrne GE; Levy R; Gascoyne RD; Lossos IS
J Clin Oncol; 2008 Jan; 26(3):447-54. PubMed ID: 18086797
[TBL] [Abstract][Full Text] [Related]
34. Treatment of gastrointestinal diffuse large B cell lymphoma in China: a 10-year retrospective study of 114 cases.
Li X; Shen W; Cao J; Wang J; Chen F; Wang C; Zou S; Shen B; Zhao R; Li J; Shen Z
Ann Hematol; 2012 Nov; 91(11):1721-9. PubMed ID: 22733613
[TBL] [Abstract][Full Text] [Related]
35. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
[TBL] [Abstract][Full Text] [Related]
36. Similar outcomes in Asian and Western patients with diffuse large B-cell lymphoma treated with R-CHOP.
Castillo JJ; Sinclair N; Beltrán BE; Song MK; Ilic I; Leppa S; Nurmi H; Seki R; Uccella S; Li JM; Treaba DO; Stachurski D; Butera JN
Leuk Res; 2013 Apr; 37(4):386-91. PubMed ID: 23352640
[TBL] [Abstract][Full Text] [Related]
37. The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients.
Troppan KT; Melchardt T; Deutsch A; Schlick K; Stojakovic T; Bullock MD; Reitz D; Beham-Schmid C; Weiss L; Neureiter D; Wenzl K; Greil R; Neumeister P; Egle A; Pichler M
Eur J Haematol; 2015 Dec; 95(6):538-44. PubMed ID: 25677782
[TBL] [Abstract][Full Text] [Related]
38. Clinical impact of bulky mass in the patient with primary extranodal diffuse large B cell lymphoma treated with R-CHOP therapy.
Song MK; Chung JS; Sung-Yong O; Lee GW; Kim SG; Seol YM; Shin HJ; Choi YJ; Cho GJ; Shin DH; Yun EY
Ann Hematol; 2010 Oct; 89(10):985-91. PubMed ID: 20428871
[TBL] [Abstract][Full Text] [Related]
39. [Clinical characteristics, cell origin and prognosis of primary gastrointestinal diffuse large B-cell lymphoma: a report of 40 cases].
Yang YL; Wang J; Zhao LZ; Gao ZF; Jing HM; Ke XY
Ai Zheng; 2008 Jun; 27(6):636-41. PubMed ID: 18570740
[TBL] [Abstract][Full Text] [Related]
40. Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era.
Takahashi H; Tomita N; Yokoyama M; Tsunoda S; Yano T; Murayama K; Hashimoto C; Tamura K; Sato K; Ishigatsubo Y
Cancer; 2012 Sep; 118(17):4166-72. PubMed ID: 22213346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
